A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Binimetinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.
- 20 Sep 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.